2. Others

Others

Others

Related Products

PDF 58.49 MB

There are a number of inhibitors, agonists, and antagonists which we cannot make precise classification because the research area is still unknown.

Others Related Products (73922):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-144013C
    18:0 mPEG750 PE ammonium 474922-77-5 98%
    18:0 mPEG750 PE (ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymeric nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.
    18:0 mPEG750 PE ammonium
  • HY-144013D
    18:0 mPEG1000 PE ammonium 474922-77-5 98%
    18:0 mPEG1000 PE (ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymeric nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.
    18:0 mPEG1000 PE ammonium
  • HY-144013E
    18:0 mPEG3000 PE ammonium 474922-77-5 98%
    18:0 mPEG3000 PE (ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymeric nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.
    18:0 mPEG3000 PE ammonium
  • HY-144015
    14:1 EPC trifluoromethanesulfonate 1246304-44-8 98%
    14:1 EPC trifluoromethanesulfonate is ethyl-phosphatidylcholine (EPC) with monounsaturated 14:1 chains. 14:1 EPC trifluoromethanesulfonate shows transfection activity. 14:1 EPC trifluoromethanesulfonate can be used for drug delivery.
    14:1 EPC trifluoromethanesulfonate
  • HY-144017
    12:0 EPC chloride 474945-22-7 98%
    12:0 EPC chloride is a cationic phospholipid. 12:0 EPC chloride can be used for drug delivery.
    12:0 EPC chloride
  • HY-144020
    14:0 DAP 72719-84-7 98%
    14:0 DAP (1,2-dimyristoyl-3-dimethylammonium-propane ) is a cationic lipid that can be used for drug delivery.
    14:0 DAP
  • HY-144023
    16:0-18:1 EPC chloride 328250-19-7 98%
    16:0-18:1 EPC chloride is a cationic lipid, which can be used for liposomes applied in drug delivery.
    16:0-18:1 EPC chloride
  • HY-144098
    HDAC8-IN-2 2824131-20-4 98%
    HDAC8-IN-2 (compound 5o) is a potent HDAC8 inhibitor, with IC50 values of 0.27 and 0.32 μM for smHDAC8 (Schistosoma mansoni histone deacetylase 8) and hHDAC8, respectively. HDAC8-IN-2 shows significant killing of the schistosome larvae. HDAC8-IN-2 markedly impairs egg laying of adult worm pairs.
    HDAC8-IN-2
  • HY-144119
    Cas9-IN-2 1030133-34-6 98%
    Cas9-IN-2 is a potent Cas9 inhibitor (IC50=246 μM), Cas9-IN-2 acts by binding to apo-Cas9 to prevent Cas9:gRNA complex formation, which can potentially be applied to modulate and control Cas9 activity in various applications.
    Cas9-IN-2
  • HY-144124
    5-C-heptyl-DNJ 2734265-63-3 98%
    5-heptyl-DNJ is a potent GAA agonist with a Ki of 0.0047 μM. 5-C-heptyl-DNJ increases GAA activities by chaperrone effects.
    5-C-heptyl-DNJ
  • HY-144141S
    Nortriptyline impurity 3-d3 hydrochloride 98%
    Nortriptyline impurity 3-d3 (hydrochloride) is the deuterium labeled Nortriptyline impurity 3 hydrochloride.
    Nortriptyline impurity 3-d3 hydrochloride
  • HY-144142S
    Orphenadrine impurity 6-d3 hydrochloride 98%
    Orphenadrine impurity 6-d3 (hydrochloride) is the deuterium labeled Orphenadrine impurity 6 hydrochloride.
    Orphenadrine impurity 6-d3 hydrochloride
  • HY-144143S
    N-Desmethyl Olopatadine-d3 hydrochloride 2768767-39-9 98%
    N-Desmethyl Olopatadine-d3 (hydrochloride) is the deuterium labeled N-Desmethyl Olopatadine hydrochloride.
    N-Desmethyl Olopatadine-d3 hydrochloride
  • HY-144144S
    (E)-N-Desmethyl Olopatadine-d3 hydrochloride 98%
    (E)-N-Desmethyl Olopatadine-d3 (hydrochloride) is the deuterium labeled (E)-N-Desmethyl Olopatadine.
    (E)-N-Desmethyl Olopatadine-d3 hydrochloride
  • HY-144145S
    Hydroxy Pioglitazone (M-II)-d4 2747917-81-1 98%
    Hydroxy Pioglitazone (M-II)-d4 is the deuterium labeled Hydroxy Pioglitazone (M-II).
    Hydroxy Pioglitazone (M-II)-d4
  • HY-144146S
    Pramipexole impurity 7-d10 98%
    Pramipexole impurity 7-d10 is the deuterium labeled Pramipexole impurity 7.
    Pramipexole impurity 7-d10
  • HY-144148S
    Pyroxsulam-13C,d3 98%
    Pyroxsulam-13C,d3 is the 13C- and deuterium labeled Pyroxsulam.
    Pyroxsulam-13C,d3
  • HY-144149S
    3'-p-Hydroxy paclitaxel-d5 98%
    3'-p-Hydroxy paclitaxel-d5 is the deuterium labeled 3'-p-Hydroxy paclitaxel.
    3'-p-Hydroxy paclitaxel-d5
  • HY-144150S
    Pelubiprofen impurity 2-13C2,d6 98%
    Pelubiprofen impurity 2-13C2,d6 is the 13C- and deuterium labeled Pelubiprofen impurity 2.
    Pelubiprofen impurity 2-13C2,d6
  • HY-144153S
    S-(1,2-Dichlorovinyl)glutathione-13C2,15N 98%
    S-(1,2-Dichlorovinyl)glutathione-13C2,15N is the 13C- and 15N-labeled S-(1,2-Dichlorovinyl)glutathione.
    S-(1,2-Dichlorovinyl)glutathione-13C2,15N